Drug Trial Radar · NCT07906106
A Proof-Of-Concept (POC) Study of SFG-02 Transdermal Formulation in Participants With Underactive Bladder (UAB)
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
70
Planned (sponsor's estimate)
Start
Aug 22, 2026
Primary completion
Feb 28, 2028
Study completion May 31, 2028
Sponsor
- Lead sponsor
- Juro Sciences Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this POC (Phase 2a) study is to evaluate the effect on Bladder Voiding Efficiency (BVE) as well as safety of SFG-02 transdermal formulation in participants with UAB. Participants will: * Apply the study patches every day for 12 weeks and wear each patch for a full day * Visit the clinic once every 2 to 4 weeks for checkups and tests * Keep diaries about their bladder symptoms and the times they change their study patches
Conditions
- Participants With Underactive Bladder (UAB)
Interventions
SFG-02Drug
Transdermal formulation containing SFG-02 1.6 mg once a day
PlaceboDrug
placebo once a day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bladder Voiding Efficiency (BVE)Time frame: The change from Baseline (Week 4) to Week 12
Locations
16 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site selected by Juro
Fukuoka, Japan · Recruiting
Clinical Site selected by Juro
Fukushima, Japan · Recruiting
Clinical Site selected by Juro
Kumamoto, Japan · Recruiting
Clinical Site selected by Juro
Nagasaki, Japan · Recruiting
Clinical Site selected by Juro
Saga, Japan · Recruiting
Clinical Site selected by Juro
Shizuoka, Japan · Recruiting
Clinical Site selected by Juro
Nagoya, Aichi-ken, Japan · Recruiting
Clinical Site selected by Juro
Ōbu, Aichi-ken, Japan · Recruiting
Clinical Site selected by Juro
Katori-shi, Chiba, Japan · Recruiting
Clinical Site selected by Juro
Yoshida-gun, Fukui, Japan · Recruiting
Clinical Site selected by Juro
Sapporo, Hokkaido, Japan · Recruiting
Clinical Site selected by Juro
Mito, Ibaraki, Japan · Recruiting
Clinical Site selected by Juro
Chiyoda-ku, Tokyo, Japan · Recruiting
Clinical Site selected by Juro
Meguro-ku, Tokyo, Japan · Recruiting
Clinical Site selected by Juro
Shinjuku-ku, Tokyo, Japan · Recruiting
Clinical Site selected by Juro
Chūō, Yamanashi, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.